Functional and Structural Characterization of LRRK2 p. V1447L in Parkinson's Disease
Movement Disorders · 2025
DOI: 10.1002/mds.30284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2025. Verfasst von Neringa Pratuseviciute und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carnegie Trust for the Universities of Scotland, MRC PPU Reagents and Services, Chief Scientist Office.
Abstract (Originalsprache)
Background
Gain‐of‐kinase‐function variants in LRRK2 are a leading cause of monogenic Parkinson's disease (PD).
Objectives
We tested the functional impact of a novel LRRK2 variant p.V1447L identified in a young‐onset PD patient in vivo in peripheral blood, as well as in a robust cellular assay, alongside other variants in close proximity to V1447.
Methods
We measured LRRK2‐dependent Rab10 phosphorylation in neutrophils and monocytes of a LRRK2 p.V1447L carrier with PD. We performed structural mapping and evaluated the potential impact of other LRRK2 variants at and around LRRK2 V1447.
Results
LRRK2 p.V1447L strongly increases LRRK2 kinase activity. We identified additional variants in the LRRK2 ROC:COR B interface with critical impact on kinase activity and demonstrated that different substitutions at the same residue can have opposing effects.
Conclusions
We recommend reclassifying LRRK2 p.V1447L from variant of uncertain significance to likely pathogenic. Our study expands the range of putative loss‐of‐kinase function variants to LRRK2 missense variants. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
- Institut du Cerveau-Paris Brain Institute ICM, Sorbonne Université, Inserm 1127, CNRS 7225, Hôpital de la Pitié Salpêtrière, Paris, France.
- Université Caen Normandie, Normandie Université, Biotargen UR7450, CHU de Caen, Service de Génétique, Caen, France.
- Département de Génétique Médicale, APHP Sorbonne Université, Paris, France.
- Division of Neuroscience, School of Medicine, University of Dundee, Dundee, UK.
ORCID-Profile: Pawel Lis, Esther Sammler
Förderung
- Carnegie Trust for the Universities of Scotland
- MRC PPU Reagents and Services
- Chief Scientist Office
Zitieren
APA
Pratuseviciute, N., Lis, P., Weber, S., Gruchy, N., Arnaud, L., Alessi, D. R., & Sammler, E. (2025). Functional and Structural Characterization of LRRK2 p. V1447L in Parkinson's Disease. Movement Disorders. https://doi.org/10.1002/mds.30284
Vancouver
Pratuseviciute N, Lis P, Weber S, Gruchy N, Arnaud L, Alessi DR, et al. Functional and Structural Characterization of LRRK2 p. V1447L in Parkinson's Disease. Movement Disorders. 2025. doi:10.1002/mds.30284
BibTeX
@article{Pratuseviciute2025,
author = {Pratuseviciute, Neringa and Lis, Pawel and Weber, Sacha and Gruchy, Nicolas and Arnaud, Lionel and Alessi, Dario R and Sammler, Esther},
title = {Functional and Structural Characterization of LRRK2 p. V1447L in Parkinson's Disease},
journal = {Movement Disorders},
year = {2025},
doi = {10.1002/mds.30284}
}
EUVIMED